Search Results

Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanobiology and machine learning analysis announced that it is collaborating with Bruker BioAFM, a business unit of Bruker, to develop the world’s first clinical diagnostic tests that leverage multi-parametric, single-cell biophysical markers and machine learning.

NanoString Technologies, Inc. (“NanoString” or “the Company”) today announced that substantially all of its assets will be acquired by Bruker Corporation (“Bruker”), a global life science analytical instrument company, for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities.

Bruker Corporation announced that it has closed its asset acquisition of the business of NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of life-science research solutions for spatial transcriptomics and gene expression analysis.

Bruker Corporation announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis.

Bruker Corporation announced it will present at the following conferences.

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech.